Answers are grounded in this paper and cite their sources.
Evaluation of FOXA1 and EZH2 IHC ratio for breast cancer subtype classification suggests a novel approach to precision oncology.
Breast cancer treatment stratification currently relies on PAM50/Prosigna (NanoString nCounter, $3,000–$4,000 per patient) for molecular subtyping, limiting precision oncology to major centres in wealthy countries. We report the derivation and multi-dataset validation of the FOXA1/EZH2 ratio as a two-stain IHC instrument for simultaneous subtype classification and treatment logic assignment across all six major breast cancer subtypes (Luminal A, Luminal B, HER2-enriched, TNBC, Claudin-low, and ILC). The ratio was derived from Waddington attractor geometry applied to 19,542 single cancer cells (GSE176078), where it correctly orders subtypes in the predicted sequence LumA > LumB > HER2 > TNBC > Claudin-low (values: LumA 9.38, LumB 8.10, HER2 3.34, TNBC 0.52, CL 0.10). This ordering was confirmed in TCGA-BRCA (n=837 PAM50-labelled patients, KW p=2.87×10^-103), with survival stratification confirmed in TCGA-BRCA (KM p=0.0031, n=1,218) and METABRIC (KM p<0.0001, n=1,980) independently, combining for n=3,198 patients across two platforms. ROC analysis (METABRIC): LumA vs Basal AUC=0.828; LumA vs LumB AUC=0.796. Independent TCGA replication: LumA vs Basal AUC=0.901; LumA vs LumB AUC=0.873. ILC is the structural exception: FOXA1 hyperactivated above normal (structural lock, CDH1 absent), EZH2 low — the ratio inverted relative to all other subtypes — requiring full ER receptor degradation (fulvestrant) as the therapeutic entry point rather than ligand depletion. Each ratio level maps directly to a therapeutic unlock logic: ratio >8 (luminal, ET engages; LumA vs LumB distinguished by CDK4/6i vs HDACi); ratio ~3 (HER2 amplicon, anti-HER2 first); ratio ~0.5 (epigenetic lock, tazemetostat + fulvestrant sequence); ratio <0.2 (no lock, immune only, anti-TIGIT then anti-PD-1 sequence). No clinical guideline, precision oncology framework, or pathology protocol uses FOXA1 and EZH2 as a combined two-stain IHC ratio to stratify breast cancer treatment logic across all subtypes. The instrument is novel. The remaining validation step is IHC calibration on stained tissue: antibody clone selection, H-score cut-point determination, and inter-observer kappa assessment — the same steps applied to ER, PR, HER2, and Ki67 before routine clinical adoption. The instrument costs an estimated $50–$100 per patient (30×–80× reduction vs PAM50) and requires no specialised equipment beyond standard IHC, enabling deployment in any pathology laboratory worldwide. This is the clinical translation gateway for the OrganismCore BRCA cross-subtype framework and directly addresses the precision oncology equity gap in low- and middle-income countries.
No takes yet. Share an insight, caveat, or question.
Eric Robert Lawson (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: